Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4461 - The prognostic role of PD-L1 expression in tumor and immune cells in oral cavity squamous cell carcinoma

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Head and Neck Cancers

Presenters

Svetlana Kutukova

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

S. Kutukova1, N. Beliak2, G. Manikhas3, G. Raskin4, Y. Ivaskova5, N. Popova1

Author affiliations

  • 1 Chemotherapy Department, City clinical oncology dispensary, 198255 - Saint-Petersburg/RU
  • 2 Chemotherapy Department, City clinical oncology dispensary, 198255 - Saint Petersburg/RU
  • 3 Head Physician, City clinical oncology dispensary, 198255 - Saint Petersburg/RU
  • 4 Department Of Pathology, Russian Research Centre for Radiology and Surgical Technologies, 197758 - St.-Petersburg/RU
  • 5 Maxillo-facial Surgery Department, City clinical oncology dispensary, 198255 - Saint-Petersburg/RU
More

Resources

Abstract 4461

Background

The programmed death-ligand 1 (PD-L1) has an important role in anticancer immunity. The aim of our study was to examine the expression and prognostic value of PD-L1 in tumor and immune cells in patient with squamous cell carcinoma of oral cavity (OCSCC).

Methods

We detected tumor samples of 60 patients with OCSCC with stage I - IVB (37 men, 23 women; median age 59). We examined demographic data, clinical stage, tumor morphological characteristics and expression of PD-L1 in tumor and immune cells (clone BCDdx1020) by immunohistochemistry (55 samples were acceptable).

Results

The expression level in tumor cells varied from 0% to 70%: in 24 (43,64%) samples expression of PD-L1% were negative (0%), in 9 (16,36%) - from 1 to 4% (low rate), in 17 (30,91%) - from 5 to 49% (moderate rate) and in 5 (9,1%) - more than 50% (high). In immune cells expression of PD-L1 varied from 0% to 15%: in 7 (12,73%) samples - negative (0%), in 30 (54,55%) - from 1 to 4% (low), in 13 (23,64%) - from 5 to 9% (moderate) and in 5(9,10%) - >10% (high). In 5 samples with high level PD-L1 expression in tumor expression PD-L1 in immune cells was negative. Median OS of patients with PD-L1-negative' tumor was 17 mo (95% CI 8-185), with low rate (1-4%) of PD-L1 expression - 9 mo (95% CI 2-36), with moderate rate (5-49%) - 13 mo (95% CI 7,5-19) and median OS in patients with high rate (>50%) not reached for this time and mean of OS is 55 mo (σ = 14,722) (95% CI 26-84). Median OS of patients with negative PD-L1-status in immune cells was 12 mo (95% CI 4-185), with low rate (1-4%) PD-L1 in immune cells - 13 mo (95% CI 7,5-34,5), with moderate rate (5-9%) - 15 mo (95%CI 9-15) and with hight rate (>10%) - 17 mo (95%CI 3-36) with strong trend of increasing OS with rise of PD-L1 expression in immune cells.

Conclusions

PD-L1 expression in tumor and immune cells are favourable prognostic factors for oral cavity squamous cell carcinoma.

Clinical trial identification

Legal entity responsible for the study

Svetlana Kutukova

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.